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Abstract
Background: Varicella zoster virus (VZV) causes varicella and herpes zoster. These vaccine preventable diseases are
common globally. Most available data on VZV epidemiology are from industrialised temperate countries and cannot
be used to guide decisions on the immunization policy against VZV in Africa. This systematic review aims to review
the published data on VZV morbidity and mortality in Africa.
Methods: All published studies conducted in Africa from 1974 to 2015 were eligible. Eligible studies must have
reported any VZV epidemiological measure (incidence, prevalence, hospitalization rate and mortality rate). For
inclusion in the review, studies must have used a defined VZV case definition, be it clinical or laboratory-based.
Results: Twenty articles from 13 African countries were included in the review. Most included studies were cross-
sectional, conducted on hospitalized patients, and half of the studies used varying serological methods for
diagnosis. VZV seroprevalence was very high among adults. Limited data on VZV seroprevalence in children showed
very low seropositivity to anti-VZV antibodies. Co-morbidity with VZV was common.
Conclusion: There is lack of quality data that could be used to develop VZV control programmes, including
vaccination, in Africa.
Trial registration: PROSPERO 2015: CRD42015026144.
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Background
Varicella zoster virus (VZV), a member of the herpesviri-
diae family, is responsible for two distinct disease entities:
varicella (chicken pox) and herpes zoster (shingles). VZV is
a ubiquitous virus and both diseases of varicella and herpes
zoster occur commonly throughout the world [1, 2].
Primary infection with VZV results in varicella, a usually
benign disease of childhood characterized by fever and a
pruritic vesicular rash. Complications, such as bacterial skin
infections, pneumonia and encephalitis, can however, occur
and may result in significant morbidity and mortality,
particularly if the primary infection occurs in adults or
those who are immunosuppressed [1].
Following the primary infection, VZV remains dor-
mant in the host. With decreased immunity, as seen in
elderly persons or with human immunodeficiency virus
(HIV)-associated immunosuppression, VZV reactivates
causing herpes zoster, a painful vesicular rash with a
dermatomal distribution. A common complication of
herpes zoster is post-herpetic neuralgia, which can result
in significant morbidity. Eye involvement, including
uveitis with the risk of blindness, can also occur. Occa-
sionally herpes zoster may present without a rash (zoster
sine herpete) and VZV neurological complications can
sometimes occur in the absence of a rash [3]. The
epidemiology of these atypical presentations of VZV is,
however, still not clear. In Africa, risk factors for VZV
include the rapidly growing elderly population [4] and a
high HIV prevalence [5].
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Molecular epidemiological analysis of VZV shows
some evidence of geographical segregation, which may
partly be explained by climatic conditions [6]. The VZV
genotype M1, belonging to clade 5, has been associated
with African origin [7]. Understanding the VZV geno-
types distribution is an important factor to consider
when implementing vaccination programs against the
diseases in any geographical setting.
Safe and effective vaccines against both varicella and
herpes zoster exist [2]. The varicella vaccine has also
been shown to be safe and immunogenic in immunosup-
pressed children, including those with HIV (provided
the child is not severely immunosuppressed and the
CD4+ T-cell count is >15%) [8, 9]. The World Health
Organisation (WHO) recommends routine childhood
vaccination against varicella in certain settings: where
varicella is ‘an important public health and socioeco-
nomic problem’; vaccination is affordable; and high vac-
cination coverage can be sustained [9]. Settings that
meet these WHO recommendations are mainly in high
income countries, where routine varicella vaccination is
now widespread [8]. This is in contrast to Africa, where
other public health priorities, suboptimal healthcare in-
frastructure, inability to reach high vaccination coverage
rates and lack of epidemiological data all contribute to
the vaccine against VZV being rarely used.
The vaccine (live attenuated VZV) used against herpes
zoster is similar to that for varicella, but the herpes zos-
ter vaccine has 14-fold more plaque-forming units of the
attenuated virus per dose [2, 10]. As of 2014, the WHO
had not issued recommendations on the routine vaccin-
ation against herpes zoster, due to limited evidence [2].
In Africa, there are several other vaccine preventable
diseases (VPD’s) associated with a greater public health
burden [11, 12], compared to VZV-associated diseases.
Immunization priorities and strategies are largely driven
by the public health burden and the severity of VPD’s.
Routine vaccination against VZV is therefore, not con-
sidered a priority in Africa. Although VZV-associated
morbidity and mortality rates are generally low in most
settings, both varicella and herpes zoster can cause con-
siderable strain on healthcare systems and society, in the
absence of preventative measures [1].
For Africa to design effective strategies that can miti-
gate the VZV-associated disease burden, it is crucial to
understand the epidemiology of both varicella and her-
pes zoster on the continent. Most of the available and
published VZV epidemiology data come from settings
such as Europe and North America [8]. This epidemio-
logical data on VZV in developed countries cannot be
extrapolated to Africa because of several differences be-
tween the two settings, including climate, the HIV epi-
demic and malnutrition [13, 14]. In addition, suboptimal
access to healthcare services may exacerbate the VZV-
associated disease burden in Africa. Data from Brazil
shows that varicella in the pre-vaccine period was asso-
ciated with significant morbidity and mortality [15].
Similar findings are, therefore, expected from some
countries in the African continent, such as South Africa.
Prior to this review, there has been no synthesised lit-
erature on VZV epidemiology in Africa. Our review
aimed to address this gap in knowledge by describing
the epidemiology of VZV in Africa, taking into account
both varicella and herpes zoster. Because HIV/AIDS is
prevalent in Africa, we were also interested in assessing
the impact of the HIV/AIDS epidemic on the epidemi-
ology of varicella and herpes zoster.
Methods
Protocol registration and publication
We registered and published a detailed description of
the methods used for this systematic review [16].
Study eligibility criteria
Studies were eligible for inclusion in this review if they
reported the epidemiology of VZV in any age group,
were conducted in any African country and reported any
outcome of interest as defined in our protocol [16]. An
additional criterion for inclusion was having a case def-
inition for the diseases.
For varicella, included studies must have stated a case
definition; failure to do which would result in exclusion.
The case definition considered for varicella is the one
used by the Centres for Disease Control and Prevention
(CDC) is [17]:
 Clinical description: An acute illness with diffuse
maculopapulovesicular rash, without other apparent
cause.
 Laboratory criteria: Isolation of varicella virus from
a clinical specimen, or varicella antigen detected by
direct fluorescent antibody test, or varicella-specific
nucleic acid detected by polymerase chain reaction
(PCR), or significant rise in serum anti-varicella IgG
antibody level by any standard serologic assay.
For herpes zoster, included studies must have stated
the clinical signs (painful maculopapulovesicular rash,
usually confined to a dermatome), as it has been shown
to be pathognomonic [18].
Systematic review outcomes
Primary outcomes
 Incidence or prevalence of varicella or herpes zoster
 Proportion of varicella or herpes zoster cases
requiring hospitalization
 Mortality associated with varicella or herpes zoster
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Secondary outcomes
 Proportion of varicella or herpes zoster morbidity or
mortality associated with HIV/AIDS
Literature search
Details of the literature search strategy are provided
in the protocol [16]. We searched from the following
databases: PubMed, Scopus, Africa-wide, Embase,
WHOLIS, PDQ-Evidence, CENTRAL, CINAHL and
Web of Science.
Study selection
Cross-sectional, cohort and intervention studies were
eligible for inclusion. All studies published from Janu-
ary 1974 to September 2015 were included without
language restrictions. For non-English articles, Google
translator software was used to translate to English, to
enable us conduct a preliminary screening based on
titles or abstracts. Subsequently, if the record needed
further scrutiny, we contacted a scientist who is a
native speaker of the language that needed translation
to English. For articles in French that appeared likely
eligible for inclusion, we sought translation support
from a native speaker within our network of
collaborators.
Screening of the selected studies
The first (HSH) and the second (LHA) authors
screened the literature search outputs using titles and
abstracts. In addition, study setting, study design,
methods as well as study outcomes were evaluated. The
two authors then independently read through the full
text of all potentially eligible studies to assess if inclu-
sion criteria were met. Discrepancies between the two
authors were resolved through discussion and consen-
sus, with the assistance of the last author (BMK). The
bibliographies of the included studies were screened for
any other relevant studies. No additional studies were
included in this review from the reference list of the
selected studies. The Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) flow
diagram (Fig. 1) illustrates the process of the study
screening and selection.
Fig. 1 PRISMA flow diagram showing the study selection process. A total of 844 records were identified during the search procedures from the 9
databases. From the total records, 321 were duplicates and therefore excluded. The remaining 523 records were subjected to screening for
inclusion/exclusion. Following the screening, 20 records met the inclusion criteria
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Data collection
Data were independently extracted from the included
studies by two reviewers, and recorded on a predesigned
form. For more information on the data collection, see
the protocol [16].
Risk of bias assessment and strength of the cumulative
results for included studies
We adapted the risk of bias and quality assessment tool
developed by Hoy et al., [19] and modified by others
[20] for prevalence studies. Two authors (HSH and
LHA) independently scored the risk of bias using the
tool, and a κ agreement was calculated.
Summary measures
The extracted data were heterogeneous and therefore,
meta-analysis was not feasible.
Synthesis and presentation of the results
Narrative reporting was used to describe the data from
the studies. The findings of this systematic review are
reported according to the PRISMA guidelines [21].
Results
The complete raw data-set is available as a supplemen-
tary file (Additional file 1: Table S1).
Study selection
The results of the searches from several database
sources are summarised in a PRISMA flow diagram
(Fig. 1). A total of 844 records were identified dur-
ing the search procedures from the 9 databases.
From the total records, 321 were duplicates and
therefore excluded. The remaining 523 records were
subjected to screening for inclusion/exclusion.
Following the screening, 20 records met the inclu-
sion criteria.
Limited VZV epidemiology data in Africa
Our first aim was to establish which countries in Africa
have reported published data on the VZV epidemiology
between 1974 and 2015. There were 20 published
studies conducted in 13 different African countries (24%
of all countries on the continent) included in the final
analysis (Fig. 2).
Available VZV epidemiology data in Africa is mainly from
cross-sectional studies
Study characteristics of the 20 included articles are
described in Table 1. Twelve (60%) studies were con-
ducted in health-care facilities, six (30%) studies were
conducted in the community and the remaining two
(10%) studies were conducted in both health-care fa-
cilities and communities simultaneously. Twelve (60%)
Fig. 2 Map of Africa. Map of Africa showing the countries where included studies were conducted. The figure legend shows the types of study
design. A total of 20 studies from 13 countries were included in the review. (Copyright was not required for this figure)
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studies were cross-sectional, five (25%) were cohort
and three (15%) were case-control. Two studies were
published in the 1980’s and one study was published
in the 1990’s. The remaining seventeen studies (85%)
were published between 2000 and 2015. The median
sample size of participants in all studies was 305
(range 47–45,000).
From the 20 studies, a total population of 92,613
participants were studied. Two large surveillance
studies from Guinea-Bissau [22, 23] contributed
largely to the reported total population. 50% of the
studies were based in urban areas (n = 10), 20% in
rural areas (n = 4) while 10% in both rural and urban
areas (n = 2). 10% of the studies were conducted in
peri-urban areas. One study was partially conducted
in an urban area and a refugee camp [24] while the
specific information on the area of study was missing
for one study [25].
Burden of VZV-associated disease in Africa is high but
variable
We evaluated the reported incidence, prevalence,
hospitalization and mortality data from the included
studies (Table 2 and Figs. 3 and 4). Across the included
studies, variable case definitions for VZV disease were
used, and these can be broadly categorised into two
types: serological and clinical. Only two (10%) studies
combined both serological and clinical criteria for the
VZV case definition. According to our results, the avail-
able data from the 13 (65%) studies on the burden of
VZV disease in Africa is mostly from adult populations.
Incidence
Of the 20 included studies, only 3 (15%) reported incidence
of VZV. Two of the three incidence studies reported vari-
cella in Guinea Bissau, and these studies were published by
the same authors and used a combination of serology and
Table 1 Study characteristics, including country and setting
Author (year of publication) Citation number Country Community OR Health facility (setting) Study Design Sample size
Schoub, B. D., et al. (1985) [37] South Africa Community cross-sectional 244
Sixl, W. and B. Sixl-Voigt (1987) [25] Cape Verde Health facility cohort 380
Ghebrekidan, H., et al. (1999) [45] Eritrea Community cross-sectional 450
Poulsen, A., et al. (2002) [22] Guinea-Bissau Community cohort 37,400
Poulsen, A., et al. (2005) [23] Guinea-Bissau Community cohort 45,000
Selim, H. S., et al. (2007) [35] Egypt Health facility cross-sectional 322
Admani, B., et al. (2008) [38] Kenya Health facility cross-sectional 182
Compston, L. I., et al. (2009) [28] Ghana Both cross-sectional 412
Ajayi, G. O., et al. (2011) [44] Nigeria Health facility cohort 70
Hannachi, N., et al. (2011) [42] Tunisia Health facility cross-sectional 404
Ben Fredj, N., et al. (2012) [33] Tunisia Both case-control 102
Nahdi, I., et al. (2012) [29] Tunisia Health facility cross-sectional 126
Benjamin, L. A., et al. (2013) [34] Malawi Health facility cross-sectional 183
Nahdi, I., et al. (2013) [30] Tunisia Health facility cross-sectional 47
Schaftenaar, E., et al. (2014) [41] South Africa Health facility cross-sectional 405
Siddiqi, O. K., et al. (2014) [32] Zambia Health facility cross-sectional 331
Asiki, G., et al. (2015) [39] Uganda Community case-control 166
Laaks, D., et al. (2015) [31] South Africa Health facility case-control 129
Leung, J., et al. (2015) [24] Somalis living in Kenya Community cross-sectional 288
Rubaihayo, J., et al. (2015) [26] Uganda Health facility cohort 5972
Table 2 Burden of VZV in Africa
Author (year of publication) Study population Case definition Incidence (per 100,000) Hospitalization & Mortality
Varicella incidence
Poulsen, A., et al. (2002) children & adults clinical & serology 441 per 100,000 NS; 0%
Poulsen, A., et al. (2005) children & adults clinical & serology 3420 per 100,000 NS; 0.13%
Zoster incidence
Rubaihayo, J., et al. (2015) adults clinical 751 per 100,000 NS; NS
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clinical tests to diagnose VZV (Table 2 and Figs. 3 and 4).
Using population registers to estimate the denominator,
ncidences of 441 per 100,000 and 3420 per 100,000 were
reported by Poulsen et al., 2002 and 2005 respectively [22,
23]. As the denominator was estimated by the authors, the
accuracy of the incidences reported is not clear. The me-
dian age for the varicella cases reported by the incidence
studies were 3 [22] and 4.4 years [23]. Co-morbidity
reported by the two incidence studies were pneumonia at
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Fig. 3 VZV Prevalence, as diagnosed by PCR. Forest plot of VZV prevalence, as diagnosed by PCR. Due to the heterogeneity of the prevalence



























































Fig. 4 VZV Prevalence, as diagnosed by serology. Forest plot of VZV prevalence, as diagnosed by serology. Due to the heterogeneity of the
prevalence data, we did not conduct meta-analyses and therefore, do not report on the pooled prevalence
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reported by Poulsen et al., 2002 were bacterial skin infec-
tions (43.6%), cough (23.6%), conjunctivitis (4%) and diar-
rhoea (1.8%). Poulsen et al., 2005 reported a case-fatality
rate of 0.13%. Poulsen et al., 2002 did not report mortality.
The study by Rubaihayo et al., 2015 diagnosed herpes
zoster clinically and reported an annual incidence of 751
per 100,000 in Ugandan HIV positive patients [26].
Median age of participants in this study was 32 years
(range 26–39) and median CD4 at antiretroviral treat-
ment (ART) initiation was 128 cells/mm3.
Prevalence
There were eight (40%) studies that reported prevalence
of VZV-associated disease quantified by viral detection
using PCR. Although expensive and requiring greater
technical expertise and resources, PCR tests, whether
quantitative or qualitative, show superior sensitivity and
specificity compared to antibody detection tests [27]. Of
the eight studies that used PCR, three were quantitative
[28–30], two qualitative [31, 32], and the remaining
three did not specify if the PCR used was quantitative or
qualitative [33–35]. Four of the eight studies were per-
formed on CSF (in patients that presented with signs of
central nervous system [CNS] infections), whereas two
studies were performed on ocular fluids (mostly from
patients with uveitis). The eight studies found a VZV
prevalence that ranged from 0% to 90% (Fig. 3). This big
variation could be explained by the fact that these stud-
ies had recruited highly selected patient populations (i.e.
patients presenting to healthcare facilities with a possible
CNS infection or uveitis). It is unlikely that the VZV
prevalence reported from these patients can, therefore,
be extrapolated to the general population.
Seroprevalence
Evaluation of antibodies to VZV (IgG, IgM or both) was
reported in ten studies (Fig. 4). IgG provides an indica-
tion of previous infection or vaccination, and therefore
immunity, while IgM suggests recent or acute infection
[36]. Nine of the ten studies measured IgG, and of these,
two also tested IgM. The nine studies used the enzyme
linked immunoassay for the antibody measurements,
while the tenth study used the complement fixation
method without specifying the type of antibody mea-
sured. A combination of commercially available kits and
inhouse immunoassays were used and there was high
variability in how the ten studies tested for anti-VZV
antibodies (IgG or IgM). In addition, cut-offs for anti-
VZV antibodies positivity were not provided except by
Schoub et al., 1985 who indicated that a 0.15 regression
value of the EIA was the cut-off positivity value [37].
The assay variability and lack of defined positivity cut-
offs partly contributed to our inability to perform a
meta-analysis on the seroprevalence in this review.
Seroprevalences ranged from 21.9% (in hospitalized
children with co-morbidities in Kenya [38]) to 100%
(elderly patients in rural Uganda [39]). In general, and as
expected in settings without routine vaccination,
children showed lower proportions of seropositivity to
VZV than adults (Fig. 4).
VZV burden and co-morbidities, including HIV
For these results, we focused on the studies that used a la-
boratory detection of the VZV in quantifying the burden
(Table 3). Our limited data did not allow us to establish an
association between VZV burden and the HIV prevalence
at a population level (Table 3). One study, however, sug-
gested that HIV infection was associated with VZV sero-
positivity [28]. Compston et al., 2009 compared the VZV
seroprevalence in healthy HIV uninfected blood donors
(45%) with symptomatic HIV patients (57.2%), and found
the odds ratio for having VZV antibodies was 1.6 (95% CI,
1.1–2.6) [28].
Nine (45%) of the 20 included studies evaluated VZV
burden in HIV infected populations. As an example,
Rubaihayo et al., 2015 assessed the trends of opportunis-
tic infections among HIV-infected persons in Uganda
and found that the VZV incidence was 1340 per 100,000
at the start of the study in 2002 in the pre-ART era,
compared to the incidence of 330 per 100,000 in 2013 in
the ART era [26].
Only one study reported VZV seropositivity (IgG) data
in pregnant women and found it to be 80.9% in Tunisia
[40]. One study, conducted among hospitalized children
in Kenya reported the rates of seroprotective antibodies
against VZV as 21.9%, 24.1% and 25.0% amongst those:
infected with HIV, with malignancies and with severe mal-
nutrition, respectively [38]. In the four studies that looked
at VZV causing CNS infections, the prevalences ranged
from 0% (of viral meningitis in adults in Malawi [34]) to
3.9% (in Zambian adults with CNS infections caused by
VZV [32]). Amongst those who presented with seizures,
VZV was diagnosed in 23.1% [32]. The patients were
highly immunosuppressed (median CD4 count was 89)
and the case fatality rate for VZV CNS infections was
30.8% [32] [Siddiqi, personal communication, 13 October
2016]. In immunocompetent patients in Tunisia, 29.8% of
uveitis cases were caused by VZV [30], while in South
Africa, 32% of uveitis cases were caused by VZV [31].
Most co-morbidities diagnosed alongside varicella or her-
pes zoster required hospitalization (e.g. severe malnutrition,
meningitis) (Table 4). This may partly explain why most
included studies were conducted in health facilities.
Risk factors for VZV infection
Several studies commented on the poor patient history
of previous VZV infection, possibly due to recall bias
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[41], and patient history often did not correspond with
serology [37, 42].
Crowded living conditions fuel the spread of VZV, and
thus affect VZV seroprevalence. VZV seropositive status
was associated with a higher number of individuals per
household in rural South Africa [41]. A study amongst
Somali refugees in Kenya noted high (94–96%) VZV
seroprevalence rates in crowded refugee camps, that had
experienced varicella outbreaks [24, 43].
Risk of bias and quality assessment
A risk of bias and quality assessment was conducted inde-
pendently by two raters using a modified assessment tool
adapted from Hoy et al. [19]. Thereafter, Cohen’s κ was run
to determine the inter-rater agreement. Moderate agree-
ment (κ =0.510) was found (Additional file 2: Table S2).
Using the average score of the two independent raters, 8
studies had a score of 6–8 points, suggesting that they were
at a moderate risk of bias, while 12 studies had a score of
8–10 points, implying that they were a low risk of bias.
Discussion
We successfully conducted a systematic review on the epi-
demiology of VZV in Africa. A high but variable burden
of VZV-associated disease was found. In this review, we
observed high VZV seroprevalence (IgG) in adults. This
review identified limited VZV seroprevalence data in chil-
dren which was insufficient to compare with data from
adults. One study by Adamani et al. showed relatively low
rates of detectable antibodies in children [38]. In contrast,
high rates of detectable VZV antibodies in adults were
reported [24, 25, 28, 37, 39, 41, 42, 44, 45]. Because
vaccination against VZV is not routine in Africa, we
presume the high seroprevalence rates in adults indicates
previous natural exposure or infection.
Although this review identified limited data on VZV in
children, increasing age, even in adults was found to be
associated with increased VZV seropositivity. A South
African study reported that only a moderately high pro-
portion of young adults had detectable VZV antibodies,
compared to all individuals at 60 years of age in the
same setting [37]. The VZV seropositive status was also
found to be independently associated with age in HIV
positive patients [41]. Taken together the VZV seroposi-
tivity results reported in this review suggests that
primary VZV infection occurs at a later age in Africa,
compared to other regions [1]. Interestingly later acqui-
sition of varicella is thought to be possibly protective
against developing shingles, as immunity developed
during the initial infection could last longer [46].
Climatic conditions are known to influence the trans-
mission of VZV [8]. Africa has widely varying climates,
including large areas of tropical and sub-tropical climates
that may result in a lower transmission of VZV and there-
fore primary infection at older ages, as has been seen in
studies from India and South East Asia [14, 47]. Our
results corroborate those of Lee et al., who reported VZV
seroconversion in Asian tropical countries peaking in ado-
lescence and adulthood [14]. In contrast, seroconversion
with VZV appears to peak during childhood in temperate
countries [48].
Exposure to VZV is cumulative over time and
seroconversion, therefore, is expected to increase with
age. Seropositivity depends on what antibody level cut
offs were used, and were unfortunately not reported for
most studies in this review. Understanding the age of
primary VZV infection in a given setting is crucial in
the design of an optimal vaccination strategy. The only
two studies that looked at varicella incidence (both
from Guinea-Bissau) reported high incidence rates in
Table 3 HIV and other co-morbidities. VZV prevalence based on









Selim, H. S., et al.
(2007)
. 0.6 meningitis/encephalitis
Ben Fredj, N., et al.
(2012)
0 4.9 multiple sclerosis
Nahdi, I., et al. (2012) 0 3.2 “acute neuromeningeal
disorder”
Benjamin, L. A., et al.
(2013)
68 0 viral meningitis
Nahdi, I., et al. (2013) 0 29.8 uveitis
Siddiqi, O. K., et al.
(2014)
100 3.9 CNS infections
Laaks, D., et al. (2015) 45.8 0–32 uveitis
Table 4 HIV and other co-morbidities
Author (year of publication) HIV positive
participants (%)
Other co-morbidities
Schoub, B. D., et al. (1985) .
Sixl, W. and B. Sixl-Voigt (1987) . febrile illness
Ghebrekidan, H., et al. (1999) .
Poulsen, A., et al. (2002) .
Poulsen, A., et al. (2005) .
Admani, B., et al. (2008) 64 severe malnutrition,
malignancies
Compston, L. I., et al. (2009) 29
Ajayi, G. O., et al. (2011) 100
Hannachi, N., et al. (2011) . pregnancy
Schaftenaar, E., et al. (2014) 100
Asiki, G., et al. (2015) 16 stroke
Leung, J., et al. (2015) .
Rubaihayo, J., et al. (2015) 100
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both children and adults [22, 23]. The incidence rates
reported in Guinea-Bissau seem higher than those
observed in some temperate climates for a similar age
group, [49, 50]. However, the Guinea-Bissau incidence
rates are comparable to pooled incidence rates reported
in Latin America [51].
Climatic conditions vary greatly between and within
African countries, and, therefore, the data from Guinea-
Bissau cannot be extrapolated to the whole continent. In
addition, high levels of household overcrowding might
negate the effect of a tropical climate on VZV transmis-
sion [8]. There were, however, eight studies that tested
for VZV using PCR, as well as two that utilised IgM,
which gave some indication of recent or current infec-
tion. Of the eight studies that utilised PCR, all excluding
the Compston et al., 2009 study, were all in patients suf-
fering from neurological or ocular diseases, and, there-
fore, cannot be extrapolated to the general population.
Important risk factors in the development of herpes
zoster include advanced age and altered cell mediated
immunity, as seen in malignancy, immunosuppressive
treatment and HIV infection [36]. HIV positive individ-
uals are thought to have a 12–17-fold greater risk of
developing zoster [13]. In Sub-Saharan Africa where the
burden of HIV is high, zoster has a high positive predict-
ive value for underlying HIV infection [13]. A study con-
ducted in Rwanda after the 1994 genocide found that
amongst HIV positive patients, post-traumatic stress dis-
order was significantly associated with zoster (the study
used patient self-reports to diagnose zoster and was,
therefore, not included in this review) [52]. In a study
amongst HIV positive patients in Zambia with CNS
infections, VZV was the fourth most common viral
infection and VZV case fatality rates were high [32]. In
comparison, a study looking at viral meningitis in
Malawi, where more than half of the patients were HIV
positive, detected no VZV co-infection [34]. This was
unexpected as VZV is a common identifiable cause of
viral meningitis in industrialised countries [34]. A study
by Compston et al. found that HIV was associated with
VZV seropositivity [28]. The authors hypothesized that
in individuals, who were previously exposed to VZV but
remained seronegative, HIV-driven immune dysfunction
leads to relatively small increases in VZV replication and
reactivation. This in turn results in boosting of VZV
antibodies and higher VZV seroprevalences in HIV [28].
The widespread and increasing availability of antiretro-
viral treatment (ART) in Africa [5] will likely have a posi-
tive impact on VZV epidemiology. Restored immune
function on ART is thought to be protective against
herpes zoster [53]. This is observed in Rubaihayo et al.,
study where the VZV incidence dramatically decreased
from the pre-ART era, compared to the ART era [26].
These findings are consistent with data from HIV positive
patients in the USA [54]. The development of zoster while
on ART has been suggested to be a marker of non-
adherence to ART [55]. Taken together, these results
suggest that HIV treatment programs should be strength-
ened when establishing vaccination programs against
VZV in African countries. It must also be noted that as
ART is allowing HIV positive people to live longer, the
HIV population in Africa is aging [56]. The implications
of an ageing HIV positive population on the epidemiology
of zoster are not clear.
Optimal vaccination programmes against VZV are
effective in mitigating the disease burden [8]. There are
currently no routine vaccination programs against VZV in
any African county unlike many developed countries, that
have adopted a universal vaccination policy against vari-
cella [8]. In 2006, some developed countries reported a
case fatality rate for varicella of 2–4 per 100,000 [50, 57].
Slightly higher case fatality rates of 11 per 100,000 were
reported in Latin America where vaccination programs
have been introduced in some countries [51]. However, as
shown in our review, case fatality rates of up to 130 per
100,000 were reported in Guinea-Bissau [23]. The VZV
associated mortality is known to be about 30 times higher
in adulthood than childhood [1]. We were not able to find
any reported rates of hospitalization from our included
studies. Rates of complications, including the development
of post-herpetic neuralgia, were also not reported.
Our review is limited by a paucity of data on VZV in
Africa. Between 1974 and 2015, only 20 studies from 13
countries met the inclusion criteria for our review. The
countries that contributed to the review may not be rep-
resentative of the continent as a whole [58]. As our
review included only published studies, and did not con-
sider grey literature, there is potential for bias in our
findings. In addition, the quality of the included studies
is also poor, as the review mostly consisted of cross-
sectional studies that depended on serology for their
case definition. The serological tests were mainly
enzyme linked assays detecting IgG, lacked information
on positivity cut-offs and the assays do not discriminate
current infection from previous infection, previous
exposure or vaccination. Furthermore, many of the stud-
ies were conducted in a health facility on patients
already hospitalized with complications of possible VZV.
While this does give us some indication of the burden
that VZV imposes on the health system, the prevalences
and mortality rates obtained from these studies cannot
be extrapolated to the general population.
Conclusion
Effective vaccines for both varicella and herpes zoster exist.
We observed low and high levels of VZV seropositvity in
children and adults respectively. The observations are wor-
risome, particularly in the context of a high HIV burden
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and an ageing population in Africa, as it suggests some pri-
mary exposure to VZV may be happening in adulthood.
Primary VZV infection is more severe in adults than chil-
dren. The resultant increased risk of morbidity and mortal-
ity from VZV could be mitigated by vaccines. Where
universal varicella vaccination may not be feasible, such as
in most African countries, vaccination of high risk individ-
uals, such as healthcare workers, immunocompromised pa-
tients and their household contacts has been suggested [8].
But improved surveillance of VZV-associated diseases and
cost-effectiveness data on the continent is first needed be-
fore vaccination can be considered. Future research must
focus on generating quality primary data and feasibility of
interventions on VZV in Africa.
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